title: Combination of gemcitabine-containing magnetoliposome and oxaliplatin-containing magnetoliposome in breast cancer treatment: A possible mechanism with potential for clinical application.
abstract: Breast cancer is a major global health problem with high incidence and case fatality rates. The use of magnetoliposomes has been suggested as an effective therapeutic approach because of their good specificity for cancers. In this study, we developed two novel magnetoliposomes, namely, Gemcitabine-containing magnetoliposome (GML) and Oxaliplatin-containing magnetoliposome (OML). These magnetoliposomes were combined (CGOML) was used to treat breast cancer under an external magnetic field. Biosafety test results showed that GML and OML were biologically safe to blood cells and did not adversely affect the behavior of mice. Pharmacokinetic and tissue distribution studies indicated that both magnetoliposomes exhibited stable structures and persisted at the target area under an external magnetic field. Cell and animal experiments revealed that CGOML can markedly suppress the growth of MCF-7 cells, and only the CGOML group can minimize the tumor size among all the groups. Finally, CGOML can significantly inhibit MCF-7cell growth both in vitro and vivo by activating the apoptotic signaling pathway of MCF-7 cells.
authors.affiliation: School of Basic Medical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, 325035, China.
authors.forename: Hui
authors.initials: H
authors.lastname: Ye
authors.affiliation: Department of Cellular and Molecular Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.
authors.forename: Jiansong
authors.initials: J
authors.lastname: Tong
authors.affiliation: School of Ophthalmology and Optometry, Wenzhou Medical University, Wenzhou, Zhejiang, 325035, China.
authors.forename: Jiangyi
authors.initials: J
authors.lastname: Liu
authors.affiliation: School of Ophthalmology and Optometry, Wenzhou Medical University, Wenzhou, Zhejiang, 325035, China.
authors.forename: Wenman
authors.initials: W
authors.lastname: Lin
authors.affiliation: School of Ophthalmology and Optometry, Wenzhou Medical University, Wenzhou, Zhejiang, 325035, China.
authors.forename: Chengshou
authors.initials: C
authors.lastname: Zhang
authors.affiliation: School of Renji, Wenzhou Medical University, Wenzhou, Zhejiang, 325035, China.
authors.forename: Kai
authors.initials: K
authors.lastname: Chen
authors.affiliation: School of The First Clinical Medical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, 325035, China.
authors.forename: Jie
authors.initials: J
authors.lastname: Zhao
authors.affiliation: School of Renji, Wenzhou Medical University, Wenzhou, Zhejiang, 325035, China.
authors.forename: Wenjing
authors.initials: W
authors.lastname: Zhu
mesh_terms: D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D001943:Breast Neoplasms / Q000188:drug therapy*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D016503:Drug Delivery Systems / Q000379:methods*; D005260:Female; D006801:Humans; D008081:Liposomes; D058185:Magnetite Nanoparticles / Q000008:administration & dosage*; D051379:Mice; D008819:Mice, Nude; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000009:adverse effects; D000077150:Oxaliplatin; D023041:Xenograft Model Antitumor Assays; D000093542:Gemcitabine
chemical_list: D008081:Liposomes; D058185:Magnetite Nanoparticles; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D003841:Deoxycytidine; D000093542:Gemcitabine
keywords: MCF-7; breast cancer; gemcitabine; magnetoliposome; oxaliplatin